What is HC Wainwright’s Estimate for VolitionRx Q3 Earnings?

VolitionRx Limited (NYSE:VNRX) – Equities researchers at HC Wainwright raised their Q3 2025 earnings per share estimates for shares of VolitionRx in a research note issued on Monday, August 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.01) per share for the quarter, up from their previous forecast of ($0.05). The consensus estimate for VolitionRx’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx’s FY2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.03) EPS.

Several other research analysts also recently commented on VNRX. Jones Trading raised VolitionRx to a “strong-buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, June 10th. Wall Street Zen started coverage on VolitionRx in a research note on Thursday, May 15th. They set a “sell” rating on the stock. Finally, D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $3.50.

VolitionRx Price Performance

Shares of VolitionRx stock opened at $0.6602 on Wednesday. The stock has a 50-day simple moving average of $0.70 and a 200-day simple moving average of $0.59. VolitionRx has a 52-week low of $0.3951 and a 52-week high of $0.94. The firm has a market cap of $71.03 million, a price-to-earnings ratio of -1.83 and a beta of 1.26.

Insiders Place Their Bets

In other VolitionRx news, CEO Cameron John Reynolds purchased 78,125 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The shares were bought at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the purchase, the chief executive officer owned 2,609,847 shares in the company, valued at approximately $1,670,302.08. This trade represents a 3.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Guy Archibald Innes acquired 78,125 shares of VolitionRx stock in a transaction that occurred on Tuesday, August 5th. The shares were purchased at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the transaction, the director directly owned 966,814 shares in the company, valued at $618,760.96. The trade was a 8.79% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 188,750 shares of company stock worth $118,175. Corporate insiders own 10.40% of the company’s stock.

Institutional Trading of VolitionRx

Several institutional investors and hedge funds have recently modified their holdings of VNRX. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the fourth quarter worth approximately $29,000. Blair William & Co. IL bought a new position in VolitionRx during the second quarter valued at $30,000. Millennium Management LLC bought a new position in VolitionRx during the fourth quarter valued at $36,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRx during the second quarter valued at $52,000. Finally, Northern Trust Corp grew its holdings in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.